



# ConCERT-D

an **idox** solution


## A Dementia Research Solution for both Clinicians and R&D

ConCERT-D™ is an electronic patient record designed specifically for the treatment of dementia patients, providing R&D Departments with the necessary tools to manage consent and easily identify eligible participants for clinical trials.

Designed by clinicians at the West London Mental Health Trust, ConCERT-D™ provides an easy to

navigate tool which, when used in clinical sessions, provides a platform that encourages all parties to contribute.

By providing results and key information on a simple display, the updating of both clinical and non-clinical records is a simple and straightforward task for clinicians.



## An Electronic Patient Record for Clinicians

ConCERT-D™ displays captured mental assessment scores for tests such as the Mini Mental State Examination (MMSE) in a graphical way enabling clinicians to relate fluctuations in scores with events that would have happened in the meantime.

The medication module allows clinicians to keep track of the patient diagnosis, prescribed drugs, related side effects, allergies and other conditions. The in-built drug formulary is specially geared towards dementia patients. The accumulative anticholinergic cognitive burden (ACB) is automatically calculated allowing clinicians to take better decisions, ultimately reducing the risks of cognitive impairment and death.

The screenshot shows a table of current medications with columns for Medication, Therapeutic Class, Dose, Start Date, Stop Date, Side Effects, and ACB Score. A 'Total ACB Score' of 3 is displayed at the bottom of the table.

Medication	Therapeutic Class	Dose	Start Date	Stop Date	Side Effects	ACB Score
Current						
Co-trimoxol	Non-specific anti-infectives	1 x 8mg qm	12/11/2014		1	0
Risperidone	Drug used in Nicotine dependence	2 x 200mg daily	21/08/2014		1	0
Other (last)	Other		08/07/2014		0	0
Aripiprazole	Atypical antipsychotics	1 x 3mg every 4 weeks	03/04/2014		0	0
Alimemazine	Anticholinergic	1 x 20mg daily	11/03/2014		1	0
<b>Total ACB Score</b>						<b>3</b>
Stagiprol	Drug used in Nicotine dependence		23/08/2014	27/08/2014	1	0
Other (last)	Other		08/07/2014	08/07/2014	0	0
Amisulpride	Atypical antipsychotics		01/04/2014	17/08/2014	1	0
Alimemazine	Anticholinergic		09/04/2014	09/04/2014	1	0
Aripiprazole	Atypical antipsychotics	3 x 24mg daily	03/04/2014	03/04/2014	0	0
Alimemazine	Anticholinergic	1 x 100mg daily	03/04/2014	03/04/2014	1	0
Aripiprazole	Atypical antipsychotics	1 x 23mg daily	03/04/2014	03/04/2014	0	0
Alimemazine	Anticholinergic		03/04/2014	03/04/2014	1	0
Chlorthalidone	Antihypertensive				1	0

The medication module also allows the clinicians to check the dosages for antidepressants and antipsychotics being taken by the patient as a percentage of the maximum dosage set for these medications.

Examples of the assessment scores display and the medication module.



## Research Register for the R&D Department

Dementia trials are seen as a major government target and the drive is to include more participants. The desired outcome is that patients can be offered additional treatment options and, in the long term, more research will be the path to understanding and curing the disease.

“Linking people with dementia with high quality research has historically been very problematic. Registering an individual’s interest has proved very effective in earlier pilot work with DemReg but the new ConCERT-D system will allow us to embed the register fully in clinical practice as it acts as both a Research Register and an Electronic Patient Record. This will allow even more people to gain access to the high quality dementia research we undertake.”


**Dr Craig Ritchie**  
 Senior Lecturer, Imperial College London  
 Honorary Consultant and R&D Director,  
 WLMHT

The ability to easily identify patients and carers that match a clinical trial’s participation criteria provides a highly effective tool to increase participation in research. The R&D Department can build the appropriate participation criteria for clinical trials in ConCERT-D™. At a click of a button the system automatically reports on patients that are eligible for participation in the study.

Once a patient is identified the R&D Departments speaks to their carers for advice. In some cases internal background checks, tests and screening are carried out. If a patient is found to be suitable and willing to take part he/she is enrolled onto the clinical trial. On the other hand if found unsuitable the reason why is logged and the patient is automatically excluded from subsequent participant searches for that trial.

ConCERT-D™ facilitates accreditation in programmes such as The Memory Services National Accreditation Programme (MSNAP) which allows hospitals to benchmark its services against national standards and provide quality assurances. MSNAP also enables staff to ensure they are making a meaningful difference to people’s lives as well as supporting implementation of national clinical excellence guidelines. ConCERT-D™ allows the clinicians to capture MSNAP information during interactions with the patient and then generate reports with the information gathered.

These reports allow the identification of trends, assessment of completeness and are of great use for assessors when rewarding accreditation. This functionality can be adapted to other similar accreditation programmes.



ConCERT-D can be used to identify and recruit consenting participants for research studies.

## Key Benefits & Financial Drivers

### FOR CLINICIANS:



Easily displays results and key information for clinicians on dashboards.



Updating of records, clinical and non-clinical, is straightforward and simple.



Displays mental assessment scores for tests in a graphical way.



Enables clinicians to relate fluctuations in assessment scores with events (medical, trial participation, etc.) that happen to the patient between assessments.



Allows clinicians to keep track of the patient's diagnosis, prescribed drugs, side effects, allergies, investigations, chronic conditions and lifestyle.



The in-built drug formulary is specially geared towards dementia patients, where drugs includes the ACB scale and hold defaults in terms of therapeutic class, frequency, dosage, route, indication, and formulation.



Automatically calculates the accumulative anticholinergic cognitive burden for drugs the patient is currently taking.



Allows clinicians to check the dosages of antidepressants and antipsychotics as a percentage of the dosage set for these medications.

### FOR R&D:



Captures and manages consent by patients and carers to participate in clinical trials.



Helps R&D build the appropriate participation criteria for clinical trials making use of care pathway specific clinical data.



Facilitates the identification of patients and carers that match the set trial's criteria.



Allows the R&D department to list eligible participants for new or ongoing clinical trials that were never approached to take part in research. Patients found unsuitable are automatically excluded in subsequent participant searches for that trial.



Manages the process of enrolling eligible participants to start participating in trials.



Facilitates accreditation in programmes such as MSNAP.



Reporting allows identification of trends within cohort and helps to manage consent better.